This updated guidance aims to assist in shared decision making in the use of appropriate corticosteroids (new or ongoing and administered by any route) during the COVID-19 pandemic in patients with musculoskeletal (MSK) and rheumatic conditions. It is published in the context of phase 3 of the response to the COVID-19 pandemic and at the onset of a
second wave. It relates to MSK service provision across primary, community and secondary care including rheumatology, orthopaedics and pain services.
It is applicable to adults and children. It reflects the potential problems that may be associated with corticosteroid use in the setting of COVID-19, while recognising the important role that appropriate and considered use of corticosteroids may have to treat patients where there are no alternative treatments.
Read the full document here.